Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Revision updated to v3.5.0; previous revision v3.4.3 has been removed.
    Difference
    0.1%
    Check dated 2026-03-21T08:37:55.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    The page shows a revision from v3.4.2 to v3.4.3. This appears to be a minor update with no changes to study content.
    Difference
    0.1%
    Check dated 2026-03-06T18:42:56.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Site-level revision notes show Revision: v3.4.2 with dates 2026-01-26 and 2026-02-12, replacing v3.4.1; this does not affect the study data or core content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-13T12:38:31.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1. No visible changes to study content or navigation.
    Difference
    0.1%
    Check dated 2026-02-05T17:19:47.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.3.4 and has removed Revision: v3.3.3, a minor metadata update that does not alter study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T03:03:36.000Z thumbnail image
  9. Check
    103 days ago
    Change Detected
    Summary
    Locations section added, listing California, Massachusetts, New York, and Texas under a single Locations heading; old state-specific location blocks replaced. HHS Vulnerability Disclosure link removed.
    Difference
    0.5%
    Check dated 2025-12-24T12:17:07.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.